[Funding alert] London-based NeoPhore Secures Additional £9.6Million in Series B Round Extension Funding
Feb 2, 2024 | By Startup Rise EU
![London-based NeoPhore secures additional £9.6million in series B round extension funding. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG.](https://startuprise.co.uk/wp-content/uploads/2024/02/London-based-NeoPhore-Secures-Additional-9.6Million-in-Series-B-Round-Extension-Funding.webp)
London-based NeoPhore secures additional £9.6million in series B round extension funding. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG.
The addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group).
NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair ('MMR') pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/04/Ghent-based-AmphiStar-Raises-E6-Million-in-Funding.webp)
[Funding alert] Ghent-based AmphiStar Raises €6 Million in Funding
Startup Rise EU
Apr 18, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2023/09/Lausanne-based-Debiopharm-Innovation-Fund-Launches-150-million-Seed-Funding-Initiative.webp)
[Funding alert] Lausanne based Debiopharm Innovation Fund Launches $150 million Seed Funding Initiative.
Startup Rise EU
Sep 29, 2023
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/04/London-based-Huzzle-Raises-E1.67-Million-in-Pre-Seed-Funding.webp)
[Funding alert] London-based Huzzle Raises €1.67 Million in Pre-Seed Funding
Startup Rise EU
Apr 17, 2024
Read also - Amsterdam-based DataSnipper Secures $100Million in Series B Round Funding
NeoPhore’s first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy. The additional Series B funding will be used to progress NeoPhore’s lead oral program, through early pre-clinical development.
Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”
Dr Robert James, Chairman of NeoPhore, said: “Over the past years NeoPhore has made tremendous strides in showing that it is possible to target the MMR pathway with small molecule inhibitors. The recent data the Company has generated and presented at an international conference leads us to believe that NeoPhore’s approach may be profoundly important. We are pleased to welcome three new Italian-based investors to our syndicate as well as further funding from existing investors. Their commitment reflects the potential value of NeoPhore’s approach that exploits the dynamics of cancer neoantigen evolution, through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. We are very excited about the next stage in the life of the Company.”
About NeoPhore Ltd
NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer.
Read also - Galway-based CitySwift Secures €7Million in Funding
Recommended Stories for You
![story](https://startuprise.co.uk/wp-content/uploads/2023/12/Dutch-Renewable-Energy-Investor-Return-Raises-Second-E100M-Growth-Equity-Investment.webp)
[Funding alert] Dutch Renewable Energy Investor Return Raises Second €100M Growth Equity Investment
Startup Rise EU Dec 8, 2023
![story](https://startuprise.co.uk/wp-content/uploads/2023/11/AIs-SaaS-Platform-Brightside-AI-is-Secures-1-Million-from-Social-Links.webp)
[Funding alert] SaaS Platform Brightside AI is Secures $1 Million from Social Links
Startup Rise EU Nov 30, 2023
![story](https://startuprise.co.uk/wp-content/uploads/2023/10/Paris-based-HCVC-Raises-75-million-of-its-Second-Round-Funding.webp)
[Funding alert] Paris- based HCVC Raises $75 million of it’s Second Round Funding
Startup Rise EU Oct 3, 2023
![story](https://startuprise.co.uk/wp-content/uploads/2024/04/Berlin-based-roclub-Raises-E4-Million-in-Seed-Funding.webp)
Berlin-based roclub Raises €4 Million in Seed Funding
Startup Rise EU Apr 25, 2024
![story](https://startuprise.co.uk/wp-content/uploads/2024/03/Manchester-based-Phagenesis-Secures-42-Million-in-Series-D-Funding.-.webp)
[Funding alert] Manchester-based Phagenesis Secures $42 Million in Series D Funding
Startup Rise EU Mar 5, 2024
![story](https://startuprise.co.uk/wp-content/uploads/2024/01/Berlin-based-Vyld-Raises-Seven-Figure-Seed-Funding.webp)
[Funding alert] Berlin-based Vyld Raises Seven-Figure Seed Funding
Startup Rise EU Jan 19, 2024